Diligence memo · auto-generated · as of July 2, 2026
Thiogenesis Therapeutics, Corp.
Thiogenesis Therapeutics, Corp. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Thiogenesis Therapeutics, Corp. operates in Pharma, based in TORONTO.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Thiogenesis Therapeutics, Corp. has raised $849K in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $253K on 2021-07-30.
Most recent recorded round closed around 2025-07-30.
Valuation (modeled)modeled
Provath models Thiogenesis Therapeutics, Corp. at approximately $302K (range $70K–$732K). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.47× the median modeled value of Pre-Seed Pharma companies in 2025–2027 (8 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 11 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 2.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 33% of Pharma peers (310 compared).
Modeled value ranks above 17% of those peers.
Closest niche peers: Mizar Therapeutics, Inc., ReEngage Therapeutics, Inc., King Therapeutics LLC, Dnp Therapeutics Inc, Protibea Therapeutics, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.